Cell Medica Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cell Medica Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C0480
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:28
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cell Medica Ltd (Cell Medica), formerly Immunocode Ltd manufactures and commercializes cellular products. The company uses various technology platforms such as chimeric antigen receptor (CAR), Dominant T cell receptor (TCR), PENTRA Antibody technology and NKT cell platform for manufacturing gene-modified immune cell products. Its pipeline products include CAR-NKT Cells, Dominant TCR and EBV- Targeted T Cells. Cell Medica collaborates with academic institutions to harness human immune system for the treatment of cancer. The company operates in Switzerland, the UK and the US. Cell Medica is headquartered in London, the UK.

Cell Medica Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cell Medica Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cell Medica Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Cell Medica Raises USD73.2 Million in Series C Financing 11
Cell Medica Raises USD78.3 Million in Series B Venture Financing 12
Delenex Therapeutics Raises US$8 Million In Series A3 Financing 13
Cell Medica Raises US$11 Million In Venture Financing 14
Partnerships 15
Cell Medica Enters into Partnership with University College London 15
Licensing Agreements 16
Cell Medica Extends Licensing Agreement with Baylor College of Medicine 16
Acquisition 18
Cell Medica Acquires Catapult Therapy TCR from Cell Therapy Catapult 18
Cell Medica Acquires Remaining 73% Stake in Delenex Therapeutics 19
Cell Medica Ltd – Key Competitors 20
Cell Medica Ltd – Key Employees 21
Cell Medica Ltd – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Corporate Communications 23
Jun 13, 2018: Cell Medica Names Julia P. Gregory As Non-Executive Director And Audit Chair 23
Feb 16, 2018: Cell Medica Appoints Kevin S. Boyle As CFO 24
Dec 07, 2017: Cell Medica Announces Appointment of Industry Leader Dr Annalisa Jenkins as Chair 25
Sep 18, 2017: Cell Medica Appoints CSO to Accelerate R&D for CAR and TCR Programmes 26
Product Approvals 27
Feb 21, 2017: Lead cancer immunotherapy candidate receives FDA fast track designation 27
Appendix 28
Methodology 28
About GlobalData 28
Contact Us 28
Disclaimer 28

List of Tables
Cell Medica Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cell Medica Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cell Medica Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Cell Medica Ltd, Medical Devices Deals, 2012 to YTD 2018 9
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cell Medica Raises USD73.2 Million in Series C Financing 11
Cell Medica Raises USD78.3 Million in Series B Venture Financing 12
Delenex Therapeutics Raises US$8 Million In Series A3 Financing 13
Cell Medica Raises US$11 Million In Venture Financing 14
Cell Medica Enters into Partnership with University College London 15
Cell Medica Extends Licensing Agreement with Baylor College of Medicine 16
Cell Medica Acquires Catapult Therapy TCR from Cell Therapy Catapult 18
Cell Medica Acquires Remaining 73% Stake in Delenex Therapeutics 19
Cell Medica Ltd, Key Competitors 20
Cell Medica Ltd, Key Employees 21
Cell Medica Ltd, Other Locations 22
Cell Medica Ltd, Subsidiaries 22

List of Figures
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Cell Medica Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Cell Medica Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Cell Medica Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Trafigura Group Pte. Ltd.-石油・ガス分野:企業M&A・提携分析
    Summary Trafigura Group Pte. Ltd. (Trafigura), a subsidiary of Trafigura Beheer B.V., is an independent commodity trading and logistics company. Its operations include trading of physical commodities, shipping and chartering, and asset management. The company sources, stores, transports and delivers …
  • Hanmi Pharmaceuticals Co Ltd (128940):企業の財務・戦略的SWOT分析
    Hanmi Pharmaceuticals Co Ltd (128940) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Quanta Services, Inc.:企業の戦略・SWOT・財務情報
    Quanta Services, Inc. - Strategy, SWOT and Corporate Finance Report Summary Quanta Services, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Mindteck (India) Limited:戦略・SWOT・企業財務分析
    Mindteck (India) Limited - Strategy, SWOT and Corporate Finance Report Summary Mindteck (India) Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Shamrock Foods Company:企業の戦略的SWOT分析
    Shamrock Foods Company - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Cellect Biotechnology Ltd (APOP):医療機器:M&Aディール及び事業提携情報
    Summary Cellect Biotechnology Ltd (Cellect Biotechnology) formerly Cellect Biomed Ltd is a clinical stage biotechnology company which develops stem cell selection technologies for the production of stem cells based products in the field of regenerative medicine. The company’s technology platform is …
  • Scholastic Corp (SCHL)
    Scholastic Corp (SCHL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company
  • Volkswagen AG (VOW3)-エネルギー分野:企業M&A・提携分析
    Summary Volkswagen AG (Volkswagen) is an automobile company involved in the design, development, production and sales of a wide range of vehicles and engines. It commercializes both passenger and commercial vehicles, including low consumption small cars and luxury class vehicles. The company sells i …
  • Hanwei Energy Services Corp (HE):石油・ガス:M&Aディール及び事業提携情報
    Summary Hanwei Energy Services Corp (Hanwei Energy) is a chemical company that develops, manufactures and distributes plastic fibre reinforced piping systems. The company’s products include anhydride and amine cured frp pipes, fittings, fixtures and flanges. It offers client solutions such as pre-te …
  • Ergon Inc:企業の戦略・SWOT・財務情報
    Ergon Inc - Strategy, SWOT and Corporate Finance Report Summary Ergon Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Uniqa Montenegro:企業の戦略・SWOT・財務情報
    Uniqa Montenegro - Strategy, SWOT and Corporate Finance Report Summary Uniqa Montenegro - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • FGL Sports Ltd.:企業の戦略・SWOT・財務情報
    FGL Sports Ltd. - Strategy, SWOT and Corporate Finance Report Summary FGL Sports Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Siemens AG (SIE):企業の財務・戦略的SWOT分析
    Siemens AG (SIE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • International Vaccine Institute:製薬・医療:M&Aディール及び事業提携情報
    Summary International Vaccine Institute (IVI) is a non-profit organization that discovers, develops and delivers vaccines. The organization's vaccines include bivalent inactivated oral cholera vaccine, Vi-DT typhoid conjugate vaccine, bivalent typhoid conjugate vaccine, shigella vaccine, norovirus v …
  • Deloitte Touche Tohmatsu Ltd:企業の戦略的SWOT分析
    Deloitte Touche Tohmatsu Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Strategic Resources Inc (STI):企業の戦略的SWOT分析
    Strategic Resources Inc (STI) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • ULURU Inc (ULUR):企業の財務・戦略的SWOT分析
    Summary ULURU Inc (ULURU) operates as a medical technology company that researches, develops, and markets wound care and muco-adhesive film products. The company’s products include Altrazeal and OraDisc. Its Altrazeal is a transforming powder dressing with Nanoflex technology for the management of e …
  • Naia Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Naia Ltd (Naia) is a funding and developing company that address regional and global medical needs. The company develops and manufactures therapeutics for metabolic and rare diseases. It provides global drug development through funding, clinical development, organizational structure and regu …
  • Saudi Industrial Investment Group (2250):企業の財務・戦略的SWOT分析
    Summary Saudi Industrial Investment Group (SIIG) is a petrochemical company that invests, improves and develops petrochemical industry. The company produces ethylene, polyethylene, hexene, polypropylene and polystyrene. It also provides benzene, propylene, cyclohexane, motor gasoline blend, and hydr …
  • Nuo Therapeutics Inc (AURX):製薬・医療:M&Aディール及び事業提携情報
    Summary Nuo Therapeutics Inc (Nuo Therapeutics), formerly Cytomedix, is a biomedical company that specializes in biodynamic therapies in the area of wound care. It focuses on commercializing cell-based technologies, which bind the regenerative capacity of the human body to trigger natural healing. T …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆